Literature DB >> 12100202

Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry.

R Gutzmer1, M Kaspari, M Vogelbruch, P Kiehl, A Kapp, T Werfel, J-P Brodersen.   

Abstract

Imiquimod (Aldara, 3M) is an immune response modifier used for the treatment of anogenital warts. We report a 55-year-old non-immunocompromised woman with extensive, human papillomavirus (HPV) 16-positive anogenital Bowen's disease. After 5 months of local treatment with imiquimod, the lesions completely regressed clinically and histologically, and HPV 16 DNA was no longer detectable. Moreover, DNA image cytometry revealed DNA aneuploidy (an indicator of prospective malignancy) in pretreatment samples but not in post-treatment samples. Therefore, imiquimod might be a treatment option for Bowen's disease, particularly in patients where other treatment modalities such as surgery are contraindicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100202     DOI: 10.1046/j.1365-2133.2002.04729.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

Review 1.  Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus.

Authors:  Rebecca E Hoedema
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

2.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

3.  Current treatment options for management of anal intraepithelial neoplasia.

Authors:  Stephen E Weis
Journal:  Onco Targets Ther       Date:  2013-06-10       Impact factor: 4.147

4.  Environmental scan of anal cancer screening practices: worldwide survey results.

Authors:  Jigisha Patel; Irving E Salit; Michael J Berry; Alexandra de Pokomandy; Mayura Nathan; Fred Fishman; Joel Palefsky; Jill Tinmouth
Journal:  Cancer Med       Date:  2014-04-16       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.